Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.96 -1.84%

-$0.18 today

Market cap
$1.31B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.24M

Average 4.58M

NVAX Deferred Revenue (Non-current)

Payments received for goods or services the company will deliver after more than one year.

Novavax, Inc.NASDAQ: NVAX

Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue (non-current) falls 12.3% from a year ago

Deferred revenue (non-current) stood at $359.27M at the end of Q1 FY2026, down 12.3% from a year earlier and up 0.1% from the prior quarter. Over 3 fiscal years it compounded at +26.0% a year.

Context

  • Deferred revenue (non-current) amounted to 34.4% of total assets at the end of Q1 FY2026, up 2.8 pp from a year earlier.
  • Deferred revenue (non-current) increased in 1 of the last 3 fiscal years.

What to watch

Whether deferred revenue (non-current) keeps falling in the next quarterly balance sheet after a -12.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$359.27M+0.1% QoQ
Last fiscal yearDec 2025
$358.94M-19.7% YoY
Year agoMar 2025
$409.56M-12.3% since
Deferred Revenue (Non-current) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.3%——
1 year-19.7%——
3-year CAGR+26.0%——
5-year CAGR——
10-year CAGR——

Deferred Revenue (Non-current) history

USD · from the balance sheet

Latest · FY2025
358.94M USD
Year-over-year change
-19.7%
4-year CAGR
+20.1%

Deferred Revenue (Non-current) vs competitors

How NVAX compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue (non-current) is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -12.3% is the 2nd highest of 3, against a peer median of -50.2%.
  • Deferred revenue (non-current) amounts to 34.4% of total assets for NVAX, versus a peer median of 0.0%.
NVAX Competitors
Deferred Revenue (Non-current) for NVAX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVAXNovavax, Inc.Mar 2026$359.27M USD-12.3%+26.0%34.4%
MRNAModerna, Inc.Sep 2026$139M USD-11.5%-39.0%1.0%
BNTXBioNTech SEJun 2026€87.56M EUR-88.9%+22.0%0.4%
PCVXVaxcyte, Inc.Jun 2026$0 USD——0.0%
VALNValneva SEMar 2026€0 EUR——0.0%
EBSEmergent BioSolutions Inc.Mar 2026$0 USD——0.0%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$0 USD——0.0%
INOInovio Pharmaceuticals, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding NVAX) —-50.2%-8.5%0.0%

Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents1.52B1.34B568.51M530.23M240.63M
Short-term Investments000392.89M494.45M
Net Receivables454.99M82.38M297.24M108.29M106.45M
Inventory8.87M36.68M41.7M8.75M11.55M
Other Current Assets56.11M86.68M166.15M32.51M125.2M
Total Current Assets2.16B1.7B1.14B1.13B978.28M
Property, Plant & Equipment (Net)228.7M400.49M490.99M300M67.7M
Goodwill131.48M126.33M127.45M107.48M113.46M
Intangible Assets4.77M0000
Long-term Investments1.65M1.66M000
Tax Assets(1.65M)(1.66M)000
Other Non-current Assets56.69M28.47M35.16M24M17.08M
Total Non-current Assets421.63M555.29M653.6M431.48M198.24M
Total Assets2.58B2.26B1.8B1.56B1.18B
Account Payables127.05M216.52M132.61M41.58M24.58M
Short-term Debt0324.88M000
Tax Payables00000
Deferred Revenue1.42B370.14M241.31M675.07M140.05M
Other Current Liabilities74.48M982.62M917.36M279.95M236.62M
Total Current Liabilities2.39B2.46B1.64B1.15B459.95M
Long-term Debt323.46M166.47M168.02M169.68M244.21M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)172.53M179.41M622.21M446.82M358.94M
Other Non-current Liabilities42.12M55.7M33.13M359.61M239.07M
Total Non-current Liabilities538.11M432.81M879.28M1.03B844.32M
Total Liabilities2.93B2.89B2.51B2.18B1.3B
Common Stock764K868K1.41M1.62M1.65M
Retained Earnings(3.62B)(4.28B)(4.82B)(5.01B)(4.57B)
Accumulated OCI(1.35M)(6.38M)2.72M(22.56M)2.01M
Other Stockholders Equity00000
Minority Interest00000
Total Equity(351.67M)(634.08M)(716.93M)(623.84M)(127.75M)
Total Debt453.99M549.78M229.08M230.42M248.81M
Net Debt(1.06B)(787.1M)(339.42M)(299.81M)8.18M

Novavax, Inc.

NASDAQ:NVAX

Intrinsic Alpha fair value

Locked

Current Price

$7.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.